Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally ...

You'll recognize the maker of this drug, which treats an issue affecting a larger percentage of the population than many ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20 | ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

July, video editor Meng Meng, 38, has been injecting herself with a weekly weight loss drug, hoping it will finally help her ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs Move over, Novo Nordisk and Eli Lilly. Why Pfizer and Roche look like top choices for investors. Pandora Zilstorff Jan 21, 2025 ...